Contineum Therapeutics Tumbles After Depression Drug Misses Primary Goal in Phase 2 — BigGo Finance
Contineum Therapeutics (CTNM) shares fell in after-hours trading after its depression drug candidate, licensed to Johnson & Johnson (JNJ), missed the primary efficacy endpoint in a Phase 2 trial. This is the second Phase 2 failure for the same molecule in less than a year. The company's focus shifts to its lung-disease program, PIPE-791. JNJ is evaluating the trial data, but no decision on further development has been made. Contineum shares declined 3.5% to $14.30 in after-hours trading, while J
How this was made
The 30-second read
Why it matters
The miss reduces the probability of success for the depression program and may shift investor focus to the company's IPF pipeline.
Market read
The trial failure is a material catalyst for CTNM, prompting immediate price decline and potential re‑rating by analysts.
What to watch
Cash runway through 2029 provides runway for PIPE‑791 development; J&J's decision on the candidate remains uncertain.
Background
Contineum Therapeutics (CTNM) licensed its depression candidate JNJ‑5120 to Johnson & Johnson. The Phase 2 trial failure follows a prior miss in multiple sclerosis, raising concerns about the molecule's viability.
Ticker impact
Contineum Therapeutics disclosed that its Phase 2 MOONLIGHT-1 trial missed the primary efficacy endpoint, causing the stock to fall 3.5% in after‑hours trading.
downward pressure, potential further decline if no mitigating news emerges
Phase‑2 failure is material for a biotech; the market already reacted with a price drop and analysts have cut success probability.
Market effects
Biotech sector may see heightened scrutiny on depression‑drug pipelines; peers could experience spillover volatility.
U.S. biotech investors may adjust exposure; limited impact beyond the sector.
Limited to investors tracking clinical‑trial outcomes; no broad macro effect.
Counterpoint
If Contineum can pivot to PIPE‑791 IPF program, the stock may recover on long‑term upside.
Key entities
- companyContineum Therapeutics
Biotech firm developing depression and IPF candidates.
- companyJohnson & Johnson
Partner holding global rights to the depression candidate.
